Open AccessT cell immunoglobulin and mucin domain‐containing molecule 3 on CD 14 + monocytes serves as a novel biological marker for diabetes duration in type 2 diabetes mellitus
Author(s) -
Yan Wenjiang,
Sun Peng,
Wei Dandan,
Wang Shuangxi,
Yang Jingjing,
Li Yihui,
Zhang Cheng
Publication year - 2016
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12523
Subject(s) - cd14 , diabetes mellitus , medicine , type 2 diabetes , peripheral blood mononuclear cell , inflammation , immunology , immune system , antibody , endocrinology , t cell , insulin resistance , biology , biochemistry , in vitro
Aims/Introduction Type 2 diabetes is a worldwide disease that is associated with increased rates of obesity and reduced physical activity. Obesity‐associated insulin resistance in type 2 diabetes is a disorder in the balance between pro‐inflammatory and anti‐inflammatory signals. T cell immunoglobulin and mucin domain‐containing molecule 3 (Tim‐3) has been reported as an important regulatory inflammation molecule, and plays a pivotal role in several inflammation‐related diseases. Materials and Methods Peripheral blood mononuclear cells were obtained from type 2 diabetes patients ( n = 31) and healthy donors ( n = 18), and Tim‐3 expression on peripheral blood mononuclear cells was evaluated by flow cytometry. Results We showed the downregulated expression of Tim‐3 on CD 14 + monocytes from type 2 diabetes patients. In addition, the upregulated expression of Tim‐3 on peripheral CD 4 + T cells and CD 8 + T cells was observed in the present study. The correlation analysis between Tim‐3 expression on CD 14 + monocytes and diabetes duration showed the longer diabetes duration time, the lower Tim‐3 expression on CD 14 monocytes. Conclusions The present results suggest that Tim‐3 might participate in the progression of type 2 diabetes by its negative regulation on these immune cells, and Tim‐3 on CD 14 + monocytes serves as a novel biological marker for diabetes duration in type 2 diabetes patients.